Urinary thymine dimers and 8-oxo-2'-deoxyguanosine in psoriasis.
Psoralen in conjunction with UVA (PUVA) is perhaps the most effective treatment for psoriasis. It is, however, a risk factor for skin cancer in these patients and there is a need to develop non-invasive assays reflective of treatment-induced DNA damage. We report here the assessment of two important lesions, thymine dimer (T<>T) and 8-oxo-2'-deoxyguanosine (8-OHdG), in the urine of psoriasis patients. It was found that, once corrected for urine concentration, the psoriatic group had significantly higher (P<0. 0001) urinary levels of thymine dimers compared to the control group. No significant differences in urinary 8-OHdG levels were noted between the psoriatic, atopic dermatitis and control groups. Therefore biomonitoring of therapy from the very start with this simple and non-invasive assay could perhaps be an effective measure of the risk involved with the treatment allowing optimization for minimal-risk therapy.
Ahmad
J
J
Division of Chemical Pathology, Centre for Mechanisms of Human Toxicity, PO Box 138, University of Leicester, Lancaster Road, Leicester, UK.
Cooke
M S
MS
Hussieni
A
A
Evans
M D
MD
Patel
K
K
Burd
R M
RM
Bleiker
T O
TO
Hutchinson
P E
PE
Lunec
J
J
D000080242:8-Hydroxy-2'-Deoxyguanosine; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004249:DNA Damage / Q000235:genetics; D003849:Deoxyguanosine / Q000031:analogs & derivatives* / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011701:PUVA Therapy / Q000009:adverse effects; D011071:Poly T / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy / Q000652:urine*; D011740:Pyrimidine Dimers / Q000652:urine*; D018570:Risk Assessment
D011740:Pyrimidine Dimers; D011071:Poly T; D000080242:8-Hydroxy-2'-Deoxyguanosine; D003849:Deoxyguanosine